Streetbeat News

Stock Prices

PFE

Pfizer Inc. (NYSE:PFE) announced that its drug ELREXFIO showed a median overall survival of 24.6 months in a Phase 2 study for patients with relapsed or refractory multiple myeloma.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:54 am

GILD

Gilead's Kite presented new data at EHA 2024 on the outpatient administration of Yescarta and Tecartus. The analysis shows that manufacturing Yescarta for second-line treatment of relapsed/refractory large B-cell lymphoma can reduce the time from leukapheresis to infusion compared to third-line+ treatment. The data builds on previous evidence linking timely infusion to better patient outcomes and supports the safety and feasibility of outpatient administration.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:39 am

CABA

Cabaletta Bio announced initial clinical data from Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201, showing no serious adverse events and promising clinical benefits. The trials are ongoing with 18 sites recruiting.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:25 am

TEM

Tempus has priced its initial public offering (IPO) of 11.1 million Class A common shares at $37 per share, raising $410.7 million. The shares will trade on the Nasdaq Global Select Market under the ticker symbol 'TEM' starting June 14, 2024. The offering is expected to close on June 17, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:01 am

VXRT

Vaxart has announced a $40 million underwritten offering of 50 million common stock shares at $0.80 per share. The offering is expected to close around June 17, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:50 am

ARM

Arm Holdings will join the Nasdaq-100 Index starting June 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:32 am

RARE

Ultragenyx has announced a $350 million public offering of 7,435,898 common shares at $39 per share and pre-funded warrants. The offering includes pre-funded warrants to purchase 1,538,501 shares at $38.999 per warrant. The gross proceeds are expected to be $350 million before expenses.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:27 am

GANX

Gain Therapeutics has announced the pricing of an $11 million public offering, which includes 7,116,547 shares of common stock at $1.35 per share and pre-funded warrants for 1,031,602 shares. The pre-funded warrants are immediately exercisable.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:25 am

BURU

NUBURU has announced its intention to appeal the NYSE's decision to delist its common stock. The company is taking steps to address the situation and maintain its listing status.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:20 am

RZLT

Rezolute has announced a $60 million public offering, pricing 11.25 million common shares at $4 per share and pre-funded warrants at $3.999 each.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 6:10 am